Abstract
Cognitive Behavioral Therapy (CBT) is an established adjunctive treatment for schizophrenia with a growing evidence base. More recently, CBT has been applied to individuals identified as being at risk for developing psychosis in an attempt to delay or prevent a transition to psychosis, to reduce symptoms and improve functioning. CBT has also been employed effectively with adolescents in the treatment of depression, post traumatic stress disorder (PTSD), anxiety disorders and eating disorders. This paper reviews the evidence for the use of CBT with the clinical high risk for psychosis population and addresses adaptations to the approach for use specifically with adolescents.
Keywords: Adolescents, clinical high risk, cognitive behavioral therapy, psychosis, psychosocial interventions
Adolescent Psychiatry
Title:Cognitive Behavioral Therapy for Adolescents at Clinical High Risk for Psychosis
Volume: 2 Issue: 2
Author(s): Kate V. Hardy and Rachel Loewy
Affiliation:
Keywords: Adolescents, clinical high risk, cognitive behavioral therapy, psychosis, psychosocial interventions
Abstract: Cognitive Behavioral Therapy (CBT) is an established adjunctive treatment for schizophrenia with a growing evidence base. More recently, CBT has been applied to individuals identified as being at risk for developing psychosis in an attempt to delay or prevent a transition to psychosis, to reduce symptoms and improve functioning. CBT has also been employed effectively with adolescents in the treatment of depression, post traumatic stress disorder (PTSD), anxiety disorders and eating disorders. This paper reviews the evidence for the use of CBT with the clinical high risk for psychosis population and addresses adaptations to the approach for use specifically with adolescents.
Export Options
About this article
Cite this article as:
Hardy Kate V. and Loewy Rachel, Cognitive Behavioral Therapy for Adolescents at Clinical High Risk for Psychosis , Adolescent Psychiatry 2012; 2 (2) . https://dx.doi.org/10.2174/2210676611202020172
DOI https://dx.doi.org/10.2174/2210676611202020172 |
Print ISSN 2210-6766 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-6774 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide
Current Pharmaceutical Design Role of Glycogen Synthase Kinase-3 in Insulin Resistance and Type 2 Diabetes
Current Drug Targets Actions of Adjunctive Nutritional Antioxidants in Periodontitis and Prevalent Systemic Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets The Detrimental Effect of Smoking on Female Fertility and IVF Success
Current Women`s Health Reviews Clinical Utility of Combined 18F-Fluoro-2-deoxyglucose Positron Emission Tomography – Computed Tomography in the Evaluation of Gastrointestinal Malignancies
Current Medical Imaging Editorial [Hot Topic: Environmental Impacts on Enzymes Involved in Drug and Steroid Metabolism Guest Editor: R.H. Waring ]
Current Drug Metabolism Circulating Tumor Cells in Cancer Therapy: Are we off Target?
Current Cancer Drug Targets Melatonin and Hypothalamic-Pituitary-Gonadal Axis
Current Medicinal Chemistry Current View from Alzheimer Disease to Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design Inhibitors of Steroidal Cytochrome P450 Enzymes as Targets for Drug Development
Recent Patents on Anti-Cancer Drug Discovery miR-27b-3p is Highly Expressed in Serum of Patients with Preeclampsia and has Clinical Significance
Endocrine, Metabolic & Immune Disorders - Drug Targets MicroRNAs in Breast Cancer Therapy
Current Pharmaceutical Design Tyrosine Kinase Receptors Signaling Revealed by Global Expression Profiles: Implications for Cancer Biology
Current Genomics Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Orphan Nuclear Receptor Modulators
Current Topics in Medicinal Chemistry Anti-inflammatory Effects of Mesenchymal Stem Cells and their Secretomes in Pneumonia
Current Pharmaceutical Biotechnology Pharmacogenomics of Osteoporosis
Current Pharmacogenomics Evaluation of Pharmacological Treatment Strategies in Traumatic Brain Injury
Current Pharmaceutical Design Systemic Involvement of IgG4-related Sclerosing Disease
Current Immunology Reviews (Discontinued)